Providers seeking to treat patients using telemedicine will be required to deliver the same standard of care as they would if they were treating them in person, at least according to a proposal from The Federation of State Medical Boards (FSMB). In fact, these new telemedicine policy guidelines intend to solidify patients' welfare.
Providers seeking to treat patients using telemedicine will be required to deliver the same standard of care as they would if they were treating them in person, at least according to a proposal from The Federation of State Medical Boards (FSMB). In fact, these new telemedicine policy guidelines intend to solidify patients’ welfare.
“The advancements and continued development of medical and communications technology have had a profound impact on the practice of medicine, and offer opportunities for improving the delivery and accessibility of healthcare, particularly in the area of telemedicine,” said the proposal’s authors. “However, state medical boards, in fulfilling their duty to protect the public, face complex regulatory challenges and patient safety concerns in adapting regulations and standards historically intended for the in-person provision of medical care to new delivery models involving telemedicine technologies.”
The State Medical Boards’ Appropriate Regulation of Telemedicine (SMART) Workgroup says the proposal aims to ensure that practitioners use telemedicine appropriately. Key considerations include determining when a physician-patient relationship is established, assuring that a patient’s personal data is kept private, and guaranteeing that patients are properly treated or prescribed medications.
Joshua Ewing, a National Conference of State Legislature health policy specialist, said that new policies about health information technology like telemedicine will be important.
“Many states are turning to telehealth as a way to address workforce challenges—particularly in rural and underserved areas,” Mr Ewing said. “I think many states also feel that telehealth is here, and here to stay. Therefore, they want to make sure they are in front of the issue with proper regulations that ensure patients receive safe, high-quality healthcare that is comparable to that which they would receive in a normal face-to-face interaction with a doctor.”
The FSMB will vote on the policy proposal in April at their annual meeting.
Around the Web
Proposed Patient-Centered Telemedicine Policy Raises Licensing Questions [Modern Healthcare]
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Study Validates Smartphone Analysis for Predicting Obstructive Sleep Apnea
November 29th 2023Findings show breathing sounds recorded by smartphones during sleep at home can reliably identify obstructive sleep apnea, presenting an innovative and accessible alternative to traditional in-laboratory polysomnography.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Researchers Identify Potential Biomarkers for SMA Motor Improvement Following Nusinersen Treatment
November 17th 2023A retrospective, exploratory analysis identifies biomarkers predictive of spinal muscular atrophy (SMA) response to nusinersen and suggests the efficacy of using machine learning algorithms to anticipate patient outcomes.
Read More
Data on Delandistrogene Moxeparvovec Can Inform Future Gene Therapies
November 17th 2023The FDA approved delandistrogene moxeparvovec-rokl (Elevidys, Sarepta Therapeutics) in June to treat Duchenne muscular dystrophy in ambulatory pediatric patients aged 4 through 5 who have a confirmed DMD gene mutation.
Read More